ANTINEOPLASTON A10

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C13H14N2O3
Molecular Weight	246.2619
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=C(CC1=CC=CC=C1)N[C@H]2CCC(=O)NC2=O

InChI

InChIKey=OQGRFQCUGLKSAV-JTQLQIEISA-N

InChI=1S/C13H14N2O3/c16-11-7-6-10(13(18)15-11)14-12(17)8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H,14,17)(H,15,16,18)/t10-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17695534 | https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C1004 | https://adisinsight.springer.com/drugs/800000762 | https://www.drugbank.ca/drugs/DB11702 | https://www.ncbi.nlm.nih.gov/books/NBK65872/

Antineoplaston A10 is a piperidinedione antineoplaston with potential antineoplastic activity. Antineoplaston A10 was originally isolated from human urine but is now synthetically derived. This agent intercalates into DNA, resulting in cell cycle arrest in G1 phase, reduction of mitosis, and decreased protein synthesis. Antineoplaston A10 may also inhibit ras-oncogene expression and activate tumor suppressor gene p53, leading to cell differentiation and apoptosis. Antineoplaston A10 has been used in trials studying the treatment of glioma, sarcoma, lymphoma, lung cancer, liver cancer, and kidney cancer, among others.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA 278 Target ID: DNA Sources: https://www.ncbi.nlm.nih.gov/pubmed/3569020	Binding Agent 1064
apoptosis 1 Target ID: apoptosis Sources: https://www.ncbi.nlm.nih.gov/pubmed/17695534	Activator 1430

PubMed

Title	Date	PubMed
Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma.	1999 Feb	10069350

Sample Use Guides

In Vivo Use Guide

Patients received Antineoplaston A10 (ANP) intravenously initially and subsequently orally. The average duration of intravenous ANP therapy was 16 months and the average dosage of A10 was 7.95 g/kg/day and of AS2-1 was 0.33 g/kg/day. The average duration of oral ANP was 19 months and the average dosage of A10 and AS2-1 was 0.28 g/kg/day.

Route of Administration: Other

In Vitro Use Guide

Direct effect of antineoplaston A10 on neutrophil apoptosis was tested in vitro after adding A-10 at a concentration of 10 ng/ml to the cellular suspensions of breast cancer patients. In vitro, antineoplaston A-10 was found to inhibit significantly the neutrophil apoptosis.

Name

Type

Language

ANTINEOPLASTON A10

Common Name

English

BENZENEACETAMIDE, N-((3S)-2,6-DIOXO-3-PIPERIDINYL)-

Systematic Name

English

ANTINEOPLASTON A 10

Common Name

English

ATENGENAL

Common Name

English

Antineoplaston A 10 [WHO-DD]

Common Name

English

BENZENEACETAMIDE, N-(2,6-DIOXO-3-PIPERIDINYL)-, (S)-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2500